Corvus Pharmaceuticals, Inc. Income (Loss) from Continuing Operations before Income Taxes, Domestic
Corvus Pharmaceuticals, Inc. (CRVS) reported Income (Loss) from Continuing Operations before Income Taxes, Domestic of -$15.28 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-12.
Financial Statements › Income Statement
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic · last filed 2026-03-12
- Corvus Pharmaceuticals, Inc. income (loss) from continuing operations before income taxes, domestic for fiscal 2025 was -$15.28M.
- Corvus Pharmaceuticals, Inc. income (loss) from continuing operations before income taxes, domestic for fiscal 2024 was -$62.29M.
- Corvus Pharmaceuticals, Inc. income (loss) from continuing operations before income taxes, domestic for fiscal 2023 was -$27.03M.
- Corvus Pharmaceuticals, Inc. income (loss) from continuing operations before income taxes, domestic for fiscal 2022 was -$41.31M.
| Period end | Income (Loss) from Continuing Operations before Income Taxes, Domestic 12 month |
|---|---|
| 2025-12-31 | -$15.28M 10-K · filed 2026-03-12 |
| 2024-12-31 | -$62.29M 10-K · filed 2026-03-12 |
| 2023-12-31 | -$27.03M 10-K · filed 2026-03-12 |
| 2022-12-31 | -$41.31M 10-K · filed 2025-03-25 |
| 2021-12-31 | -$43.24M 10-K · filed 2024-03-19 |
| 2020-12-31 | -$6.00M 10-K · filed 2023-03-28 |
| 2019-12-31 | -$46.67M 10-K · filed 2022-03-10 |
| 2018-12-31 | -$47.10M 10-K · filed 2021-03-25 |
| 2017-12-31 | -$28.25M 10-K · filed 2020-03-09 |
| 2016-12-31 | -$11.38M 10-K · filed 2019-03-07 |
| 2015-12-31 | -$31.34M 10-K · filed 2018-03-01 |
| 2014-12-31 | -$161.00K 10-K · filed 2017-03-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Apnimed, Inc. (APMD) | United States | $0.899B |